by Irene Morgenstern | Jun 29, 2022
PsychoGenics Strengthens Executive Team to Boost CNS Drug Discovery and CRO Capabilities Biopharmaceutical Industry Veterans David Bleakman and Thomas Oakley Each Bring Three Decades of Experience to the Company Paramus, N.J., June 28, 2022 – PsychoGenics Inc....
by Irene Morgenstern | Mar 15, 2022
Can you give an overview of how business has evolved for PsychoGenics over the past year? There are two sides to PsychoGenics; a preclinical CNS focused CRO and drug discovery. On the CRO side, PsychoGenics experienced significant growth with our service business...
Recent Comments